Toxicities have limited the use of allogeneic hematopoietic cell transplantation (HCT) to
younger, medically fit patients. In a canine HCT model, a combination of postgrafting …

After the transplantation of unmodified marrow from human leukocyte antigen-matched
unrelated donors receiving cyclosporine (CSP) and methotrexate (MTX), the incidence of acute …

Risk factors for grades 2-4 acute graft-versus-host disease (GVHD) and for chronic GVHD as
defined by National Institutes of Health consensus criteria were evaluated and compared in …

We report the results of a phase III open-label, randomized, multicenter trial comparing
tacrolimus/methotrexate to cyclosporine/methotrexate for graft-versus-host disease (GVHD) …

Postgrafting cyclosporine (CSP) given for 35 days resulted in establishment of stable marrow
grafts from DLA-identical canine littermates after otherwise suboptimal, but nevertheless, …

… Nash is a principal scientist at the Institute of Marine Research, Bergen, Norway. Nash
can be contacted at Richard.Nash@imr.no. Valencia is an associate professor at Facultad de …

Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …

Previous studies of risk factors for acute graft-versus-host disease (GVHD) involved patients
receiving predominantly single-agent prophylaxis. Therefore, a retrospective analysis was …

Results of previous studies have suggested that transplantation-related mortality among
patients with chronic graft-versus-host disease (GVHD) may be reduced by combined treatment …

Chronic graft-versus-host disease (GVHD) requires long-term immunosuppressive therapy
after hematopoietic cell transplantation. We retrospectively analyzed a cohort of 751 patients …